Incyte Corporation (Wilmington, DE). 2024 revenue ~$4.1B. JAKAFI (ruxolitinib) for myelofibrosis. Opzelura (ruxolitinib cream). Monclara (itacitinib). JAK1/2 inhibitor pioneer. CAR-T pipeline with MorphoSys.
12:54:05 AM · Jul 9, 2026
Sign in to reply and join the conversation.